NZ237176A - Insulin cobalt iii complex compositions - Google Patents

Insulin cobalt iii complex compositions

Info

Publication number
NZ237176A
NZ237176A NZ237176A NZ23717691A NZ237176A NZ 237176 A NZ237176 A NZ 237176A NZ 237176 A NZ237176 A NZ 237176A NZ 23717691 A NZ23717691 A NZ 23717691A NZ 237176 A NZ237176 A NZ 237176A
Authority
NZ
New Zealand
Prior art keywords
insulin
iii
ins
pharmaceutical composition
composition according
Prior art date
Application number
NZ237176A
Other languages
English (en)
Inventor
Jorgen Frederick Hansen
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NZ237176A publication Critical patent/NZ237176A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
NZ237176A 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions NZ237176A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK045590A DK45590D0 (en:Method) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
NZ237176A true NZ237176A (en) 1991-12-23

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ237176A NZ237176A (en) 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (en:Method)
JP (1) JPH05503940A (en:Method)
AU (1) AU641991B2 (en:Method)
CA (1) CA2075982A1 (en:Method)
DE (1) DE69100626D1 (en:Method)
DK (1) DK45590D0 (en:Method)
HU (1) HUT63858A (en:Method)
IE (1) IE910579A1 (en:Method)
NZ (1) NZ237176A (en:Method)
PT (1) PT96841A (en:Method)
WO (1) WO1991012817A1 (en:Method)
ZA (1) ZA911279B (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
KR101186851B1 (ko) 2003-08-05 2012-10-02 노보 노르디스크 에이/에스 신규의 인슐린 유도체
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー/エス 新規のインスリン誘導体
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー/エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー/エス プロテアーゼ安定化インスリンアナログ
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP6199956B2 (ja) 2012-04-11 2017-09-20 ノヴォ ノルディスク アー/エス インスリン製剤
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
SI3055325T1 (en) 2013-10-07 2018-05-31 Novo Nordisk A/S NEW DERIVATIVE ANALOGUE INSULINE
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
IE910579A1 (en) 1991-08-28
AU641991B2 (en) 1993-10-07
HUT63858A (en) 1993-10-28
HU9202721D0 (en) 1992-12-28
AU7337891A (en) 1991-09-18
EP0516704A1 (en) 1992-12-09
JPH05503940A (ja) 1993-06-24
WO1991012817A1 (en) 1991-09-05
ZA911279B (en) 1991-10-30
DE69100626D1 (de) 1993-12-16
PT96841A (pt) 1991-11-29
EP0516704B1 (en) 1993-11-10
DK45590D0 (en:Method) 1990-02-21
CA2075982A1 (en) 1991-08-22

Similar Documents

Publication Publication Date Title
NZ237176A (en) Insulin cobalt iii complex compositions
US5266333A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
DE3880346T2 (de) Insulinderivate.
DE69425464T2 (de) Polysaccharidderivat und wirkstoffträger
DE69722397T2 (de) Insulin-derivate und ihre verwendung
DE69736780T2 (de) Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
US5045312A (en) Physiologically active compositions of growth hormone and serum albumin or Ig G
Zhang et al. Polymer–covalent organic frameworks composites for glucose and PH dual‐responsive insulin delivery in mice
DE69631824T2 (de) Biologisch abbaubare nanopartikel mit kontrollierter freigabe von insulin
DE69429169T2 (de) Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält
EP0193917A2 (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
EP3554534B1 (en) Insulin containing pharmaceutical compositions
EP0646379A1 (en) Insulin formulation
WO1995005848A1 (en) Protracted glp-1
ZA200600846B (en) Novel insulin derivatives
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
CN109069590A (zh) 包含聚山梨酯80的胰岛素制剂
JPH10511365A (ja) 遅延性glp−1組成物
EP0119650A2 (en) Galactosyl-insulin conjugates useful in treating diabetics
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
JPH04504117A (ja) グリコシル化インシュリン
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
CA2463769A1 (en) Composition and method for treating diabetes
KR20110014564A (ko) 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도